首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model
【24h】

Angiopoietin-2 Inhibition Rescues Arteriovenous Malformation in a Smad4 Hereditary Hemorrhagic Telangiectasia Mouse Model

机译:血管血红素-2抑制在SMAD4遗传出血性毛细管扩张小鼠模型中抢救动静脉畸形

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Hereditary hemorrhagic telangiectasia is an autosomal dominant vascular disorder caused by heterozygous, loss-of-function mutations in 4 transforming growth factor beta (TGF beta) pathway members, including the central transcriptional mediator of the TGF beta pathway, Smad4. Loss of Smad4 causes the formation of inappropriate, fragile connections between arteries and veins called arteriovenous malformations (AVMs), which can hemorrhage leading to stroke, aneurysm, or death. Unfortunately, the molecular mechanisms underlying AVM pathogenesis remain poorly understood, and the TGF beta downstream effectors responsible for hereditary hemorrhagic telangiectasia-associated AVM formation are currently unknown.
机译:背景:遗传性出血性Telangiectasia是由4种转化生长因子β(TGFβ)途径构件中的杂合,功能性突变失异的常染色体显性血管障碍,包括TGFβ通路的中央转录介质Smad4。 SMAD4的丧失导致形成不恰当的,动脉和静脉之间的形成易碎的连接,称为动静脉畸形(AVM),这可能导致中风,动脉瘤或死亡。 不幸的是,AVM发病机制的潜在分子机制仍然明白,并且目前未知,负责遗传性出血性毛细管扩张性AVM形成的TGFβ下游效应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号